Nurse Loses Drug-Prescribing Rights in Swift DEA Revocation
Published Date: 2/21/2025
Notice
Summary
Jason Weakley, a nurse practitioner, lost his DEA registrations for Vermont and New Hampshire because he no longer has permission to handle controlled substances in those states. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his certificates. This means he can’t legally prescribe or manage controlled drugs in these states anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registrations Revoked; Renewals Denied
The DEA revoked Jason Weakley’s Certificates of Registration Nos. MW7073757 (Vermont) and MW7551460 (New Hampshire), so he cannot legally prescribe, dispense, or handle controlled substances in Vermont or New Hampshire. The Order also denies any pending applications to renew, modify, or obtain additional registration in those two states. The Order is effective March 24, 2025; the record shows his Vermont RN and APRN licenses were expired and suspended as of January 15, 2024, and his New Hampshire RN and APRN licenses expired March 23, 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-02935 — Combined Notice of Filings
The Federal Energy Regulatory Commission got new requests from natural gas companies to change pipeline rates and agreements starting as soon as February 1, 2025. These changes could affect how much customers pay or get refunded. If you want to speak up or get involved, you need to act by the listed deadlines in February and March.
Next: 2025-03023 — Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting on March 6-7, 2025, both in Washington, DC, and online. They’ll discuss important topics like tax issues for disabled workers, disaster experiences, and ethics training, with a special chance for the public to share their thoughts. This meeting affects people with disabilities, advocates, and anyone interested in disability rights, with no new costs but plenty of fresh ideas and updates.